Dobendan Strepsils Dolo

Quick links

Choose a section

Quick links to important sections

Advertisements

Dobendan Strepsils Dolo

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Dobendan Strepsils Dolo

Property Description
Active Ingredients Benzocaine, Cetylpyridinium
Form Lozenge (Lutschtablette)
Pharmacological Class Local anesthetic and Antiseptic
General Purpose Symptomatic relief of throat and mouth pain
Origin Synthetic Combination Product

Classification and Purpose of the Oral Therapeutic Agent

Dobendan Strepsils Dolo is an oral therapeutic agent recognized for its role in temporarily mitigating acute discomfort in the throat, primarily positioned for adults and adolescents facing symptoms like difficulty swallowing. Formulated as a lozenge (Lutschtablette), this medicine is a combination product that distinctly combines two pharmacological actions: local anesthesia and antiseptic activity. This preparation provides symptomatic relief directly to the affected tissues via the oromucosal route of administration. The lozenge format is specifically designed for localized, targeted action to deliver high concentrations of active ingredients directly to the inflamed area. This confirms that the primary role of the medicine is to quickly address the local sensation of pain and discomfort.

Composition: The Dual Action of Benzocaine and Cetylpyridinium

The core of this medicine is its pairing of two synthetic active ingredients: Benzocaine and Cetylpyridinium. Benzocaine acts as a fast-onset ester-type local anesthetic that temporarily numbs the pain receptors in the mucosal lining. Cetylpyridinium complements this action as a cationic disinfectant and antiseptic, helping to maintain surface hygiene by addressing microorganisms present in the oral cavity. The strategic combination of these components differentiates the product, offering an approach that simultaneously addresses pain sensation and surface microenvironment to provide comprehensive initial relief during a common sore throat episode. This highlights the value of the dual-component strategy in providing simultaneous pain relief and surface disinfection.

Advertisements

What side effects are possible with Dobendan Strepsils Dolo?

Possible Side Effects and Safety Information

The safety profile for lozenges containing Benzocaine and Cetylpyridinium is structured according to official regulatory classifications, which document specific adverse reactions and usage restrictions.


Adverse Reaction Classification

Official labeling classifies potential side effects based on how often they have been reported. For this combination, all listed adverse events are categorized with a frequency of Not Known. This classification indicates that the incidence rate cannot be accurately estimated from the available post-marketing data.

The officially documented reactions are grouped into the following System-Organ Classes:

  • Blood and Lymphatic System Disorders
  • Immune System Disorders
  • Skin and Subcutaneous Tissue Disorders

Serious Adverse Reactions and Key Restrictions

The most serious, though rare, documented safety risk associated with the Benzocaine component is Methemoglobinemia. This blood disorder can severely impair the blood's ability to transport oxygen. Symptoms officially associated with this condition include pale, gray, or blue-colored skin, headache, shortness of breath, and fatigue. Regulatory documents note that symptoms can appear within minutes to hours after administration.

The lozenge is contraindicated and must not be used in specific situations, including:

  • In children aged less than 6 years.
  • In individuals with a history of or suspected Methemoglobinemia.
  • In patients with a known allergy to Benzocaine, other ester-type local anesthetics, or any component of the lozenge.

Use requires caution in individuals with swallowing difficulties due to the local anesthetic effect. For pregnancy and lactation, use is restricted to situations where the potential benefit outweighs the possible risks, as adequate studies are not available.

This framework ensures that official safety communications clearly define prohibited populations and classify potential risks according to established standards.

Advertisements

Overdose and Emergency Response

The official overdose profile for this lozenge formulation focuses on the severe, systemic risk associated with Benzocaine. The most critical documented concern is the potential for Methemoglobinemia, a life-threatening condition that impairs the blood's ability to carry oxygen. Regulatory documents classify the overdose risk as potentially severe and life-threatening due to the possibility of respiratory or cardiac compromise.

Clinical Manifestation Severe Outcome Required Emergency Action
Cyanosis (blue/gray skin/lips) Apnoea or respiratory arrest Seek immediate medical attention
Shortness of breath Tachycardia or arrhythmias Contact emergency services
Headache, confusion, fatigue Seizures Upon signs of cyanosis or breathing difficulty

Overdose may present with confusion, a rapid heart rate, or low blood pressure. Population-specific warnings note that individuals with pre-existing heart or lung conditions, the elderly, and children under two years old are at increased risk for serious complications. Management in a healthcare setting is typically symptomatic and supportive; Methylene blue is the established intervention for documented methemoglobinemia.


The overdose profile is defined by the systemic consequences of Methemoglobinemia, detailing the cardinal manifestations such as cyanosis and dyspnea. This structure establishes a clear, mandated threshold for action, explicitly instructing users to seek immediate medical attention when these specific physiological changes are observed.

Advertisements

Therapeutic Uses of Dobendan Strepsils Dolo

The lozenge is commonly used to help provide focused, short-term symptomatic relief for symptoms related to physical discomfort associated with inflammatory or irritative states in the throat and mouth.


Targeting Severe Throat and Pharyngeal Pain

This medication is primarily used to address the pronounced, high-intensity pain associated with acute conditions characterized by periods of heightened symptoms, such as pharyngitis (throat inflammation) and painful episodes of tonsillopharyngitis. The combination of ingredients is included under the analgesic/anaesthetic and antiseptic categories to provide temporary relief of pain in the sore throat. It is applied in contexts marked by increased discomfort or tension, relevant when supportive symptom management is appropriate. Its purpose is the symptomatic moderation of distressing pain manifestations, offering temporary support that supports the patient during difficult episodes by easing distress.

Management of Painful Swallowing (Dysphagia) and Oral Inflammation

The lozenge is relevant when severe local pain leads to functional strain, specifically the difficulty and pain associated with swallowing (dysphagia). It also helps address symptom clusters that appear suddenly or fluctuate, affecting the mouth lining (stomatitis) and gums (gingivitis), relevant for managing symptoms that interfere with daily comfort.

“The medication is commonly used to help manage temporary discomfort when symptoms interfere with routine activities like speaking or swallowing.”

Providing this symptomatic relief assists with maintaining functional stability when acute manifestations interfere with essential activities like food intake, and supports patients during episodes of heightened discomfort during challenging symptomatic phases.

Quick Fact: Relief for Acute Localized Pain

Regulatory References

  1. Health Canada Throat Lozenges Monograph
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Dobendan Strepsils Dolo

This medicine, typically containing either Flurbiprofen or Benzocaine/Cetylpyridinium, is subject to strict population-eligibility rules defined by regulatory authorities. The Flurbiprofen variant is generally permitted for adults and adolescents over 12 years of age.

Absolute Contraindications

The lozenge is contraindicated in patients with known hypersensitivity to the active ingredients or excipients. For the Flurbiprofen (NSAID) variant, contraindications also include a history of allergic reactions (such as asthma) to aspirin or other NSAIDs, severe heart, hepatic, or renal failure, and active or recurrent peptic ulcers or gastrointestinal hemorrhage. The medicine is also non-eligible for patients with hereditary conditions such as fructose intolerance.

Age and Reproductive Status

The Flurbiprofen lozenge is contraindicated in children under 12 years of age, while the Benzocaine/Cetylpyridinium variant is contraindicated in children under 6 years of age. Use in older adults requires caution due to limited clinical experience. The Flurbiprofen lozenge is contraindicated during the last trimester of pregnancy and is not recommended for use by women who are breastfeeding or attempting to conceive.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products


The official regulatory profile for this lozenge primarily outlines contraindicated combinations based on known interaction patterns with its active component, Benzocaine. The documented constraints are classified into two core types: pharmacodynamic antagonism and altered systemic clearance.

Co-administration with Sulphonamide antibiotics is formally contraindicated. This prohibition is rooted in the Benzocaine metabolite, para-aminobenzoic acid (PABA), which causes a pharmacodynamic antagonism that compromises the antibacterial efficacy of Sulphonamide drugs.

The lozenge is also officially contraindicated for use with Cholinesterase Inhibitors. This restriction is a pharmacokinetic interaction because these inhibitors reduce the clearance of the local anesthetic component, increasing the risk of systemic exposure. The same restriction applies to patients with documented reduced cholinesterase activity.

No mandatory timing requirements are documented in the labeling for non-contraindicated substances. Finally, the regulatory text includes a population-specific contraindication for use in patients with a known or increased risk of developing Methemoglobinemia due to the Benzocaine component.

Advertisements

Mechanism of Action

Mechanism of Peripheral Nociceptive Signal Inhibition

The anesthetic component, Benzocaine, exerts its primary effect by engaging the Voltage-Gated Sodium Ion Channels ( Na V) found on sensory nerve endings in the throat mucosa. Its molecular action is a conduction blockade, where the molecule binds to and prevents the influx of Na^+ ions required for nerve firing. This interruption of the electrical cascade prevents the generation and transmission of nociceptive signals to the brain, resulting in the functional interruption of local sensory signal transmission.

Microbial Surface Membrane Disruption

The secondary mechanistic domain involves the cationic surfactant activity of Cetylpyridinium. This positively charged molecule targets the negatively charged components of the microbial cell membrane, physically inserting itself and disrupting the membrane's structural integrity. This direct physical action causes the targeted cells (such as bacteria) to lose their ability to regulate internal balance, resulting in cell lysis and a subsequent decrease in the local concentration of viable microorganisms on the oropharyngeal surface.

Functional Complementarity and Dual Action

The medicine's overall combined mechanistic outcome is shaped by the simultaneous operation of these two distinct mechanisms. The inhibition of nerve signaling contributes to a quick onset of suppressed sensory transmission by arresting the propagation of the sensory nerve impulse, while the membrane disruption mechanism concurrently works to modulate the local surface microbial ecology. This combination of sensory nerve impulse blockade and surface microbial membrane disruption ensures that two biological processes contributing to the local inflammatory state are modulated in parallel.

Advertisements

Dosage and Administration Information

How to Use Dobendan Strepsils Dolo

This section describes the administration and dosage protocols for Dobendan Strepsils Dolo lozenges.


Administration Method and Dosing Regimens

Dobendan Strepsils Dolo is designated for oromucosal administration, meaning the lozenge is intended for localized application to the mucosal tissues of the mouth and throat. The procedural instructions mandate that the lozenge must be allowed to dissolve slowly in the mouth to achieve the intended topical effect; it must not be chewed or swallowed whole.

Standard Use and Frequency

Population Unit Dose Minimum Interval Maximum Daily Dose
Adults & Adolescents (ge 12 years) One lozenge Every two hours 8 lozenges (in 24 hours)
Children 6–12 years One lozenge Every four hours 4 lozenges (in 24 hours)

Administration is structured for as-needed symptomatic use, with dosage strictly constrained by both the minimum interval and the 24-hour maximum limit.

Duration and Age Restrictions

The treatment is defined as short-term, and the lozenges should generally not be used for more than 3 consecutive days without medical consultation. The use of this specific lozenge combination is restricted in children under 6 years of age, for whom the medicine is not indicated.

The following parameters define the standardized approach for the use of the Benzocaine/Cetylpyridinium lozenge formulation.

Advertisements

Recent Clinical Evidence

Flurbiprofen 8.75 mg Lozenges: Overview of Research

The active ingredient in Dobendan Strepsils Dolo is flurbiprofen (8.75 mg), a non-steroidal anti-inflammatory drug (NSAID) formulated for local delivery to the throat. Clinical research primarily focuses on the product's use for the short-term symptomatic relief of acute pharyngitis (sore throat).


Efficacy and Symptom Relief Studies

Randomized, double-blind, placebo-controlled trials have been conducted to evaluate the effects of the 8.75 mg lozenge dose on various symptoms of sore throat. Key outcomes measured include the severity of throat pain, the sensation of a swollen throat, and difficulty swallowing.

  • Throat Pain: Studies have reported that the lozenge administration was associated with a reduction in throat pain intensity compared to placebo, with effects generally noted after 15 to 45 minutes and sustained for several hours.
  • Difficulty Swallowing (Dysphagia): Reductions in patient-reported difficulty swallowing scores have been documented over a 2-to-3-hour assessment period in some trials.
  • Sensation of Swelling: The effect on the subjective feeling of throat swelling has also been an endpoint in efficacy studies, with some research indicating a difference compared to placebo.

Use with Antibiotics

Exploratory analyses of data from patients with laboratory-confirmed streptococcal pharyngitis (strep throat) have examined whether the symptomatic effects of the flurbiprofen lozenge were altered by the concomitant use of antibiotics. These analyses suggest that the observed differences in relief of pain, difficulty swallowing, and throat swelling versus placebo were maintained regardless of concurrent antibiotic therapy initiation.

Key Studies & References

  1. Symptomatic treatment of acute pharyngitis with flurbiprofen 8.75 mg lozenges: a pooled analysis of three clinical trials
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dobendan Strepsils Dolo (FAQ)

Q: What are the most commonly described side effects associated with the lozenge?

Official documents classify the frequency of most potential side effects as 'Not Known,' meaning it is difficult to accurately estimate how often they occur from available post-marketing data. As with any medicine, regulatory guidance recommends that any adverse reaction be reported to a healthcare professional.

Q: Is the temporary numbing sensation of the mouth or tongue considered a normal effect?

The temporary numbing is consistent with the lozenge's function, as the active ingredient is a local anesthetic intended to block pain signals in the throat. Official product warnings advise caution during use due to this local anesthetic effect, particularly regarding swallowing, which is why lozenges must be dissolved slowly.

Q: Is there official information about using Dobendan Strepsils Dolo while pregnant?

Official guidance indicates that adequate studies are limited regarding the use of this medicine during pregnancy. Therefore, its use is restricted to situations where the potential benefit for the patient is considered to outweigh any possible risk.

Q: Is there official information about using Dobendan Strepsils Dolo while breastfeeding?

Official product information indicates that data on whether the active ingredients pass into human milk is limited. Similar to pregnancy, use while breastfeeding is generally advised only if the potential benefit is considered to outweigh the possible risks.

Q: What is methemoglobinemia, and is it a described risk associated with the active ingredient benzocaine?

Methemoglobinemia is a serious, yet rare, blood disorder that impacts the blood’s ability to transport oxygen efficiently throughout the body. Official regulatory documents identify this as a documented safety risk specifically associated with the local anesthetic component, Benzocaine. Symptoms described in the official warnings can include pale, gray, or blue-colored skin.

Q: How quickly should the pain relief effect of the lozenge typically begin?

Studies and official information for similar local anesthetic products suggest that the onset of pain-relieving action often begins within minutes after the lozenge starts to dissolve. The formulation is intended to provide targeted relief directly to the throat area.

Q: How long is the numbing or analgesic effect expected to last after the lozenge dissolves?

According to clinical data, the local numbing effect of the lozenge is sustained. Clinical data suggests the duration of effect is generally sustained for at least 30 to 45 minutes after the lozenge has fully dissolved in the mouth.

Q: Does Dobendan Strepsils Dolo contain an NSAID (non-steroidal anti-inflammatory drug) like flurbiprofen?

Official regulatory documents confirm that this lozenge does not contain flurbiprofen or any other Non-Steroidal Anti-inflammatory Drug (NSAID). The composition consists of two active ingredients: Benzocaine (a local anesthetic) and Cetylpyridinium chloride (an antiseptic).

Q: Can individuals with a history of heart or blood pressure conditions use this lozenge?

The official product information does not list heart or high blood pressure conditions as specific contraindications or required cautions for the Benzocaine/Cetylpyridinium formulation. The official contraindications address allergies, age restrictions, and specific systemic drug interactions.

Q: Do the lozenges contain any form of sugar or sweeteners that may be a concern for diabetics?

Regulatory excipient lists detail the presence of various sugars or sweeteners, such as sucrose, glucose, or sorbitol, depending on the specific product formulation. Patients managing diabetes may wish to consult the full excipient list on the packaging for their specific formulation.

Q: Are there specific signs of a hypersensitivity or allergic reaction to the ingredients a person should look for?

Official warnings advise patients to be aware of signs of a severe hypersensitivity reaction. These symptoms may include swelling of the face, tongue, or throat (angioedema), difficulty breathing, and a rapid onset of severe rash or hives.

Q: Is it safe to consume drinks or food immediately after using a Dobendan Strepsils Dolo lozenge?

Due to the numbing effect caused by the local anesthetic component, regulatory documents advise patients to avoid eating or drinking immediately after use. This caution is in place to reduce the risk of accidentally biting the tongue or cheek, or the risk of accidental inhalation due to reduced sensation.

Q: What should be done if sore throat symptoms continue or worsen after the recommended period of use?

The duration of treatment is strictly defined as short-term, typically a maximum of three consecutive days. Official guidance indicates that if symptoms persist, do not improve, or worsen after this period, consultation with a doctor is recommended.

Q: Does the lozenge help to reduce inflammation or swelling in the throat area?

Official product information describes the medicine's mechanism as a combination of local anesthetic (numbing) and antiseptic action. Regulatory documents do not make claims that the lozenge has specific anti-inflammatory properties or that it reduces swelling in the throat.

Q: Does the medicine contain any ingredients derived from wheat or gluten-containing sources?

Regulatory documents list all excipients contained in the lozenge but typically do not require specific source disclosure for common food derivatives like wheat or gluten, unless it results in a mandatory allergen warning. Patients with celiac disease or severe gluten intolerance may need to check the full product excipient list.

Q: Can the lozenge cause digestive side effects such as nausea or stomach upset?

The adverse reaction profile for this type of product commonly includes reports of gastrointestinal disorders. These may include digestive side effects such as nausea, vomiting, or abdominal pain.

Q: Is the feeling of a burning or tingling sensation in the mouth considered a possible side effect?

Official side effect listings often include localized reactions in the oral cavity. These reactions can involve a burning sensation, local irritation, or tingling in the mouth or throat area.

Q: Can the lozenge be used if a person also has a cough or cold symptoms?

The official indication for the lozenge is strictly for the symptomatic relief of mouth and throat pain. Regulatory documents do not provide specific instructions or data regarding its concurrent use with non-throat symptoms such as a cough or a general cold.

Q: Can I use other oral sprays or mouthwash while taking Dobendan Strepsils Dolo?

While specific drug interactions are detailed, regulatory information does not provide general guidance on the concurrent use of non-contraindicated oral hygiene products like mouthwash or other throat sprays. Patients may wish to observe if using multiple products affects the numbing action of the lozenge.

Q: Is it true that this product is only available for purchase in a pharmacy setting?

National drug registers commonly classify this product as a Pharmacy (P) Medicine or equivalent in certain regions. This classification means it is available without a prescription but is generally restricted to sale only in a licensed pharmacy setting.

Q: Is there any research evidence describing the effectiveness of this specific lozenge combination?

Regulatory documents are supported by the summary of clinical trials and pharmacodynamic studies conducted for this specific formulation. This research evidence describes the combined efficacy of the two active ingredients, Benzocaine and Cetylpyridinium.

Advertisements

How should Dobendan Strepsils Dolo be stored and disposed of?

How to Store and Dispose of Dobendan Strepsils Dolo

Storage and disposal must strictly follow the official regulatory guidelines to maintain product quality and environmental safety.

Official Storage Requirements

Condition Requirement
Temperature Store below 25 C. Do not refrigerate or freeze.
Protection Keep in the original container to protect from light and moisture.
Stability Do not use the lozenges after the expiry date (EXP) printed on the packaging.
Safety Keep out of the sight and reach of children.

Disposal Instructions

To ensure proper environmental protection, expired or unused lozenges must not be disposed of in household waste or wastewater. The official instruction is to consult a pharmacist for guidance on how to safely and responsibly discard the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dobendan Strepsils Dolo found in:

A-Z Index: